EGFR and non-small cell lung carcinoma: Advanced non-small-cell lung cancer (NSCLC) that harbors characteristic mutations in epidermal growth factor receptor (EGFR) is highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) [1].